PMID- 38428877
OWN - NLM
STAT- MEDLINE
DCOM- 20240304
LR  - 20240304
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 103
IP  - 9
DP  - 2024 Mar 1
TI  - Comparison of efficacy and safety of 5-FU or capecitabine combined with cisplatin 
      and docetaxel (mDCF and mDCX) as a first-line chemotherapy regimen in her 
      2-negative metastatic gastric cancer patients: A retrospective study.
PG  - e37259
LID - 10.1097/MD.0000000000037259 [doi]
LID - e37259
AB  - The prognosis of metastatic gastric cancer (GC) is poor, with a median survival 
      time of less than a year. Capecitabine is a prodrug, metabolized by thymidine 
      phosphorylase to its cytotoxic metabolite (5-FU). Few studies have compared 
      capecitabine and 5-FU in mGC. In this retrospective study, we compared the 
      efficacy and safety of modified DCF (mDCF) (docetaxel, cisplatin, and 5-FU) and 
      modified DCX (mDCX) (docetaxel, cisplatin, and capecitabine) regimens for 
      first-line treatment in patients with mGC. The study included 112 mGC patients 
      treated with either mDCF (n = 69) or mDCX (n = 43) between 2010 and 2021. 
      Demographic data, response rate, progression-free survival (PFS), overall 
      survival (OS), and adverse events were evaluated. The complete response rate in 
      the mDCF group was 10.1%, whereas the complete response rate in the mDCX group 
      was 2.3%. The partial response rate for mDCF and mDCX were 29% and 37%, 
      respectively. The 2 treatment arms of the study had the same objective rate of 
      response and disease control rate (DCR). PFS and OS rates were comparable between 
      the 2 groups. The median PFS in the mDCF and mDCX arms were 6.0 months (95% CI, 
      4.87-7.14) and 5.0 months (95% CI, 4.10-5.90) respectively (P = .08). The median 
      OS in the mDCF and mDCX arms were 9.0 months (95% CI, 7.53-10.47) and 9.0 months 
      (95% CI, 6.87-11.11) respectively (P = .07). Neutropenia, asthenia, stomatitis, 
      and nausea/vomiting were the most frequently reported grade 3 to 4 adverse events 
      (AEs). The rates of grade 3/4 AEs and dose reduction were comparable between the 
      2 groups. There was no treatment discontinuation due to grade 3 to 4 AE. As a 
      first-line treatment for patients with mGC, mDCX and mDCF regimens have 
      comparable efficacy and tolerability profiles.
CI  - Copyright (c) 2024 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Demirci, Nebi Serkan
AU  - Demirci NS
AD  - Department of Medical Oncology, Cerrahpasa University Faculty of Medicine, 
      Istanbul, Turkey.
FAU - Azizy, Abdulmunir
AU  - Azizy A
AUID- ORCID: 0000-0002-5068-6472
AD  - Department of Medical Oncology, Istanbul University Institute of Oncology, 
      Istanbul, Turkey.
FAU - Paksoy, Nail
AU  - Paksoy N
AD  - Department of Medical Oncology, Tekirdag Dr. Ismail Fehmi Cumalioglu City 
      Hospital, Tekirdag, Turkey.
FAU - Dogan, Izzet
AU  - Dogan I
AD  - Department of Medical Oncology, Basaksehir Cam and Sakura City Hospital, 
      Istanbul, Turkey.
FAU - Karabulut, Senem
AU  - Karabulut S
AD  - Department of Medical Oncology, Istanbul University Institute of Oncology, 
      Istanbul, Turkey.
FAU - Karahan, Latif
AU  - Karahan L
AD  - Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, 
      Turkey.
FAU - Tastekin, Didem
AU  - Tastekin D
AD  - Department of Medical Oncology, Istanbul University Institute of Oncology, 
      Istanbul, Turkey.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 15H5577CQD (Docetaxel)
RN  - Q20Q21Q62J (Cisplatin)
RN  - 6804DJ8Z9U (Capecitabine)
RN  - U3P01618RT (Fluorouracil)
RN  - 0 (Taxoids)
SB  - IM
MH  - Humans
MH  - Female
MH  - *Stomach Neoplasms/pathology
MH  - Docetaxel/therapeutic use
MH  - Cisplatin/adverse effects
MH  - Capecitabine/adverse effects
MH  - Retrospective Studies
MH  - Fluorouracil/adverse effects
MH  - Taxoids/adverse effects
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
MH  - Treatment Outcome
PMC - PMC10906642
COIS- The authors have no funding and conflicts of interest to disclose.
EDAT- 2024/03/02 10:42
MHDA- 2024/03/04 06:44
PMCR- 2024/03/01
CRDT- 2024/03/01 19:23
PHST- 2024/03/04 06:44 [medline]
PHST- 2024/03/02 10:42 [pubmed]
PHST- 2024/03/01 19:23 [entrez]
PHST- 2024/03/01 00:00 [pmc-release]
AID - 00005792-202403010-00036 [pii]
AID - 10.1097/MD.0000000000037259 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2024 Mar 1;103(9):e37259. doi: 10.1097/MD.0000000000037259.